AAIC 2025 Abstract
Real‐World Use of Lecanemab With Consideration of Race, Ethnicity, and Geographical Diversity
By Jose A. Soria-Lopez, Michael Henry Rosenbloom, Marwan N. Sabbagh, Show 10 more authorsDaryl Jones
Study in peoplePopulations
Abstract
Background: Lecanemab‐irmb (LEQEMBI®) is indicated for the treatment of patients with Alzheimer’s disease (AD) in the mild cognitive impairment or mild dementia stage. Racial and ethnic disparities in access, care, and outcomes exist in AD.
